IgniteData Appoints Dr. David Rhew to Board of Directors

IgniteData appoints Dr. David Rhew, Microsoft's Global Chief Medical Officer, to its Board of Directors. Rhew brings decades of experience in healthcare, technology, and clinical research. He will help IgniteData accelerate its mission to revolutionize clinical trials and improve access to life-saving treatments.

IgniteData, a leading provider of intelligent clinical trial data automation solutions, has appointed Dr. David Rhew to its Board of Directors. Dr. Rhew brings extensive experience in healthcare, technology, and clinical research, having served as Microsoft's Global Chief Medical Officer and Vice President of Healthcare. His appointment marks a significant milestone in IgniteData's mission to revolutionize clinical trials and improve access to life-saving treatments.

Dr. Rhew's background includes pioneering the development of evidence-based order sets integrated into electronic health records (EHRs) and serving as Microsoft's International Coordinator for the Pandemic Response. He has also played a pivotal role in launching global initiatives like the Trustworthy & Responsible AI Network [TRAIN] and the Alliance for Healthcare from the Eye. His appointment underscores IgniteData's commitment to leveraging technology to enhance clinical trial efficiency and patient outcomes.

IgniteData's CEO, Zach Taft, expressed enthusiasm about Dr. Rhew's addition to the board, stating, "We are thrilled to welcome Dr. Rhew to our board. David's expertise spans Microsoft and decades of global leadership in clinical innovation and policy. At IgniteData, we are already setting the standard for data-driven, patient-centered clinical research. With David's leadership, we will accelerate the momentum we've built and continue to define how AI and digital health transform clinical trials today."

Dr. Rhew's appointment coincides with IgniteData's advancements in clinical trial transformation. The company's Archer platform is already deployed at leading cancer centers and integrated into global studies. The platform combines IgniteData's proven interoperability with AI-powered orchestration, addressing one of the most pressing challenges in clinical trials: how to bring trials to successful endpoints faster and deliver therapies at scale.

IgniteData's mission aligns with Dr. Rhew's vision of using technology to improve lives and healthcare outcomes. "IgniteData is at the forefront of how AI and clinical data interoperability can transform trials," said Dr. Rhew. "I chose to join IgniteData's board because I believe in their mission — not just to improve workflow efficiency, but to expand access to clinical trials, improve patient outcomes, and help deliver life-saving therapies at scale. This is about technology helping to improve the lives of people, and I'm excited to help ensure that these innovations make a real-world impact."

References:
[1] https://www.stocktitan.net/news/SILO/silo-pharma-s-ptsd-candidate-spc-15-achieves-positive-safety-wjahptasqdmn.html
[2] https://www.prnewswire.com/news-releases/ignitedata-appoints-dr-david-rhew-global-chief-medical-officer-of-microsoft-to-board-of-directors-302535235.html